2012 BASHH statement on partner notification for sexually transmissible infections
H McClean, K Radcliffe, A Sullivan and I Ahmed-Jushuf
Int J STD AIDS published online 18 June 2013
DOI: 10.1177/0956462412472804

The online version of this article can be found at:
http://std.sagepub.com/content/early/2013/06/18/0956462412472804.citation
2012 BASHH statement on partner notification for sexually transmissible infections

H McClean FRCP*, K Radcliffe MA FRCP†, A Sullivan MD FRCP‡ and I Ahmed-Jushuf FRCP MBA§

*Chair BASHH National Audit Group; †Chair BASHH Clinical Effectiveness Group; ‡BASHH National Audit Group Representative Clinical Effectiveness Group; §Chair BASHH Clinical Standards Unit, British Association of Sexual Health and HIV (BASHH), Chester House, 68 Chestergate, Macclesfield, Cheshire SK11 6DY, UK

CONTENTS

(1) Summary of key principles
(2) Importance of partner notification
(3) Aim
(4) Statement development
(5) Audience and care networks
(6) Competency in partner notification (PN) practice
(7) Offering PN
(8) Infections for which PN should be offered and look-back intervals
(9) Table showing look-back intervals for partner notification and where epidemiological treatment is recommended
(10) Agreed contact actions
(11) PN resolution
(12) Legal issues regarding sharing of information between services
(13) PN auditable outcome measures for the BASHH Clinical Effectiveness Group Guidelines and National Audit Group audit questionnaires
(14) Updated chlamydial PN outcome standards and rationale for the updated standards
(15) Interface between PN and outbreak/incident control
(16) Safeguarding children and vulnerable adults
(17) HIV-PN
(18) Future developments in PN outcome measurement
(19) Contributors
(20) Document review plan
(21) Appendix. Notes on measuring the updated chlamydial PN outcome measures
(22) References

(1) Summary of key principles

- Healthcare workers (HCWs) providing partner notification (PN) should have documented competencies appropriate to the care given. These competencies should correspond to the content and methods described in the Society of Sexual Health Advisers (SSHA) Competency Framework for Sexual Health Adviser;
- All services involved in managing sexually transmitted infections (STIs) should follow the NICE Guidance on one-to-one interventions to reduce transmission of STIs;
- Services providing PN should have written care pathways linking all providers of STI care and PN to local Level 3 services included in service operational policies that are easily accessible to HCW services;
- If the offer of discussion of PN is declined, the reason for this should be documented in the patient record;
- The appropriate look-back interval and use of epidemiological treatment should be used in PN;
- Performance in PN provision should be included in service quality monitoring, and audited at least annually using the process outcome measures in this Statement (see below);
- Services providing PN should have written guidance in service operational policies, that are easily accessible to HCWs, on when to collaborate with local Health Protection Units (HPUs), including the management of outbreaks of STIs;
- Services providing PN should have written guidance in service operational policies that are easily accessible to HCWs on the use of data for safeguarding children and vulnerable adults. This guidance should be in accordance with the most recent BASHH Guideline on the Management of Sexually Transmitted Infections and Related Conditions in Children and Young People, and local guidance on safeguarding adults and the Mental Capacity Act 2005;
- Services should keep up-to-date with developments in data collection for PN, including data collection methods that facilitate quality improvement activity.
detection, reducing onward infection and re-infection, and the complications of infection. PN also involves providing other sexual health needs, including managing risk behaviour and ethical issues.

Re-infection with chlamydial and gonorrhoeal infection is common, underscoring the importance of PN for the care of both people with infection and their sexual partners. A Cochrane review has shown moderately strong evidence for effectiveness of PN in providing access to care for contacts of STIs, including HIV infection. Another systematic review has shown that interventions supplementing patient referral for STIs improve PN outcomes. The major contribution of PN to the cost effectiveness of the UK National Screening Programme has also been demonstrated.

(3) Aim
The aim of this Statement is to outline general principles on good PN practice, and to provide a resource for quality improvement activity. In particular, the Statement aims to promote consistency in the use of terms and measurements in order to improve the quality of data collected for audits. Where appropriate, future BASHH Clinical Effectiveness Group (CEG) guidelines (including in the ‘auditable outcome measures’ sections) and National Audit Group (NAG) audit questionnaires should refer to this Statement for recommended practice and performance measurement for PN. This Statement is not intended to provide the operational detail involved in PN practice, which is described in the SSHA Manual (and which is currently under review).

(4) Statement development
There are currently many different statements relating to PN process outcomes in the BASHH CEG Guidelines. This was discussed in a BASHH Clinical Standards Unit (CSU) meeting in January 2011, when it was decided to produce a statement on PN practice that would support a set of uniform PN process outcome measures that could be referred to in future BASHH CEG Guidelines and by BASHH NAG audit questionnaires. Additionally, it was agreed that the results of the BASHH 2011 audit against the BASHH Medical Foundation for AIDS and Sexual Health (MedFASH) Standards should be used to update the existing chlamydial PN process outcome measures (which were also based on performance data in audits). An agreed early version of the Statement was produced by the BASHH NAG, CEG and CSU and posted during October to November 2011 on the BASHH CEG public web page for consultation. After use of the consultation feedback, and consultation with the UK Society of Sexual Health Advisers and experts in the field, further drafts were produced and final version was agreed. This included additional sections, including legal, health protection and safeguarding issues.

The recommendations in this document are presented as a statement because, unlike a guideline, the recommendations made are not mainly based on empirical evidence, but on accepted practice, current performance (with regard to the justifications for the updated chlamydial PN performance standards), and other guidance, including the look-back intervals stated in BASHH guidelines.

(5) Audience and care networks
The intended audience for this Statement are all those HCWs, managers, commissioners and other workers involved in the provision, initiation, commissioning or support of PN. Recommendation 4 in the National Institute of Clinical Excellence evidence-based guidance on one-to-one interventions to reduce the transmission of STIs specifies a wide range of HCWs taking action to ‘Help patients with an STI to get their partners tested and treated (partner notification) …’. This includes referral to specialist centres if necessary. The BASHH and MedFASH STI management Standards set a standard of clear clinical care pathways linking STI care networks to local Level 3 STI management services and leadership.

(6) Competency in PN practice
HCWs providing PN should have documented competencies appropriate to the care given. These competencies should correspond to the content and methods described in the SSHA Competency Framework for Sexual Health Advisers. Appropriately trained medical staff may contribute to the PN process.

(7) Offering PN
At least one discussion (which may be a face-to-face or telephone discussion) should be offered to people found to have the infections listed in the table below to begin the PN process. This discussion should be provided by an HCW with the appropriate documented competency. If the offer of discussion of PN is declined, the reason for this should be documented.

(8) Infections for which PN should be offered and look-back intervals
The table in Section 9 lists the infections for which PN should be offered, together with the corresponding look-back intervals, and whether or not epidemiological treatment of contacts is recommended. The appropriate look-back interval for PN should be used. The look-back interval is the time during which the index case may have been infectious and transmitted infection, and should be applied to all contacts whether or not condoms were used. The look-back intervals and recommendations on epidemiological treatment stated are consistent with those in the BASHH CEG Guidelines, although for chlamydial infection, there is more qualification based on the presence or absence of symptoms; the current BASHH CEG Chlamydia Guideline states four weeks for [all] symptomatic infection and six months for [all] asymptomatic infection. However, there is lack of evidence to support the use of specific look-back intervals. For example, although most positive chlamydial contacts have last had sex with index chlamydial index cases in the three months before the latter’s diagnosis, important numbers of positive contacts have had sexual contact (much) earlier than this interval. Hence, these look-back intervals are for guidance and every case should be individually assessed on the basis of the sexual history, risk assessment and particular circumstances. There may be benefit, if feasible, in offering PN for some contacts earlier than these look-back intervals (including to at least the last sexual contact), and but also justification for not offering PN within these specified intervals. The use of look-back intervals should be appropriately documented.

(9) Table showing look-back intervals for PN and where epidemiological treatment is recommended
<table>
<thead>
<tr>
<th>Infection</th>
<th>Look-back intervals for partner notification</th>
<th>Epidemiological treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chancroid</td>
<td>All contacts since and in the 10 days prior to the onset of symptoms. For cases with urethral symptoms: all contacts since, and in the four weeks prior to, the onset of symptoms. For all other cases: all contacts in the six months prior to presentation.</td>
<td>Yes</td>
</tr>
<tr>
<td>Chlamydial infection</td>
<td>Use the look-back intervals for chlamydial infection or gonorrhoea, if these are detected. If these infections are not detected, the look-back interval is for all contacts since, and in the six months prior to, the onset of symptoms.</td>
<td>Yes</td>
</tr>
<tr>
<td>Epiddymo-orchitis</td>
<td>Male index cases with urethral symptoms: all contacts since, and in the two weeks prior to, the onset of symptoms. For all other cases: all contacts in the three months prior to presentation.</td>
<td>Yes</td>
</tr>
<tr>
<td>Hepatitis A†</td>
<td>Index cases with jaundice: all contacts in the two weeks prior to, and one week after, the onset of jaundice. Index cases without jaundice: if possible, estimate when infection is likely to have occurred based on a risk assessment. Notify the local CCDC or equivalent, if there are household contacts, concerns about food or water borne infection, or the index case is a food handler.</td>
<td>No</td>
</tr>
<tr>
<td>Hepatitis B†§</td>
<td>PN should include any sexual contact (vaginal or anal sex, or oro-anal sex) or injection equipment sharing partners during the period in which the index case is thought to have been infectious. The infectious period is from two weeks before the onset of jaundice until the index case is surface antigen negative. In cases without jaundice, if possible, estimate when infection is likely to have occurred, based on a risk assessment. In cases of chronic infection, trace contacts as far back as any episode of jaundice, or to the time when the infection is thought to have been acquired, although this may be difficult for long look-back intervals. Appropriate repeat serological testing of contacts should be offered.</td>
<td>No</td>
</tr>
<tr>
<td>Hepatitis C†§</td>
<td>The infectious period for acute hepatitis C is from two weeks before the onset of jaundice. However, usually there is no jaundice or history to suggest acute infection, and the look-back period for PN is to the likely time of infection (e.g. blood transfusion or first sharing of injection equipment), although this may not be possible for long look-back intervals. However, PN should be offered in two situations only, where:</td>
<td>No</td>
</tr>
<tr>
<td>HIV infection§</td>
<td>An estimate, based on a risk assessment, of when infection is likely to have occurred should be made and PN provided to include all contacts since, and in the three months prior to, this estimate. If this is not possible, all previous partners should be contacted and offered HIV testing. The risk assessment should take into account sexual history, HIV testing history (including antenatal and Blood Transfusion Service testing history) and history of possible seroconversion illness. Additionally, any results for recent infection testing algorithm (RITA) assays for HIV infection, as well as CD4 cell counts and trend in CD4 cell counts should be taken into account, although careful interpretation of these data is needed.</td>
<td>Postexposure prophylaxis where indicated – see BASHH Guidelines</td>
</tr>
<tr>
<td>LGV infection</td>
<td>For cases with symptoms: all contacts since and in the four weeks prior to the onset of symptoms. For cases without symptoms: all contacts in the three months prior to LGV detection.</td>
<td>Yes</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Infection</th>
<th>Look-back intervals for partner notification</th>
<th>Epidemiological treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-specific (non-chlamydial, non-gonococcal) urethritis in men</strong></td>
<td>Male index cases with symptoms attributable to urethritis: all contacts since, and in the four weeks prior to, the onset of symptoms Yes</td>
<td><strong>Non-specific (non-chlamydial, non-gonococcal) urethritis in men</strong></td>
</tr>
<tr>
<td></td>
<td>(Screening of men, without clinical features suggesting urethritis, by microscopy is not recommended practice, and therefore PN is not recommended for this group)</td>
<td></td>
</tr>
<tr>
<td><strong>Pelvic inflammatory disease</strong></td>
<td>Use the look-back intervals for chlamydial infection or gonorrhoea, if these are detected. If these infections are not detected, the look-back interval is for all contacts since, and in the 6 months prior to, the onset of symptoms**</td>
<td></td>
</tr>
<tr>
<td><strong>Phthirus pubis infestation</strong></td>
<td>All contacts since, and in the three months prior to, the onset of symptoms Yes – current sexual partner(s) only</td>
<td></td>
</tr>
<tr>
<td><strong>Scabies infestation</strong></td>
<td>All contacts (including non sexual contacts: those with prolonged skin-to-skin contact, bed and clothes sharing, and household contacts) since, and in the two months prior to, the onset of symptoms Yes – current sexual partner(s) and current non-sexual contacts</td>
<td></td>
</tr>
<tr>
<td><strong>Syphilis</strong></td>
<td>* Early syphilis:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>† Primary syphilis: all contacts since, and in the three months prior to, the onset of symptoms Yes – current sexual partner(s) and any other partners connected with recurrent syphilis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>† Secondary and early latent syphilis: all contacts since, and in the two years prior to, the onset of symptoms Yes – current sexual partner(s) and current non-sexual contacts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>† Late latent and late syphilis: PN of sexual partners and children of female patients should be done back to the date of the last negative syphilis serology, if available. Otherwise, it should extend back over the patient’s sexual lifetime as far as is feasible. Because of the possibility of congenital syphilis, consideration should also be given to the testing of mothers of patients with late syphilis who were born outside the UK in countries where suboptimal antenatal care was a possibility Not for latent and late syphilis</td>
<td></td>
</tr>
<tr>
<td><strong>Trichomoniasis</strong></td>
<td>Any partner(s) within the four weeks prior to presentation should be treated†</td>
<td></td>
</tr>
</tbody>
</table>

†If there have been no sexual contacts in these intervals: the most recent sexual contact beyond this interval

1Acute infectious hepatitis (caused by hepatitis A, B and C) are diseases notifiable (to Local Authority Proper Officers) under the Health Protection (Notification) Regulations 2010 Health Protection Agency25

2CCDC, Consultants in Communicable Disease Control (or Consultants in Health Protection) are responsible for the surveillance, prevention and control of communicable disease (as well as the health aspects of non-communicable environmental hazards) for a defined population within (a) defined local authority area(s). They work, along with specialist nurses, in the Health Protection Agency network of HPUs in England. HPUs work closely with other local services involved in disease detection, surveillance and control, including local microbiology laboratories. There are equivalent systems in Wales and Scotland25

3PN should be offered at follow-up visits when there are new sexual contacts, and to discuss re-testing of current partners and testing of children, where appropriate

4The six-month look-back interval for PID is given arbitrarily on the basis that *Mycoplasma genitalium* may cause disease in women and be asymptomatically carried in men and women for an unknown period.24 Also, false-negative chlamydial nucleic acid amplification tests, as well as discordant chlamydial test results, and different rates of spontaneous clearance of chlamydial infection, between sexual partners, are possible.25

5Trichomonal infection appears to resolve spontaneously in most men, usually within two weeks, with detection rates in men decreasing with increasing time from last sexual contact with female index cases. However, prolonged asymptomatic carriage has been demonstrated in some men.26–28
(10) Agreed contact actions

When the first PN discussion takes place, a plan should be agreed with the index patient, and documented, about which contacts to contact and, if so, how this should be done. All contacts in the appropriate look-back interval should be included. All contacts include those considered not traceable, as well as those who had attended a service for management of the relevant infection before the index patient was first seen. In deciding whether a contact is traceable, appropriate use of all information sources should be considered.

Possible contact actions are: patient, provider or contract methods of PN (see p. 20 of the Manual for Sexual Health Advisers6 for definitions of these methods), or no action. No action is appropriate when a contact is considered not traceable, or a contact has been verified as already seen. Not traceable may include contacts who cannot be contacted by patient, provider or contract methods of PN because of lack of information, or because of patient preference or welfare needs not to involve a contact. However, there may be circumstances requiring a “best interests” obligation to break confidentiality (e.g. when the health of another person is at risk), when local policies should be followed.

These recommendations should be used together with the operational detail provided in the SSHA Manual for Sexual Health Advisers6 and the BASHH UK National guidelines on undertaking consultations requiring sexual history taking,29 as well as the soon-to-be-published SSHA Competencies.11

(11) PN resolution

PN resolution (the outcome of an agreed contact action) for each contact should be documented within four weeks of the date of the first PN discussion, but see the comments about HIV PN in the table in Section 9. Documentation about outcomes may include the attendance of a contact at a service for the management of the infection, testing for the relevant infection, the result of testing and appropriate treatment of a contact. A record should be made of whether this is based on index case report, or verified by a HCW. Verified means confirming contact attendance by checking records in your own service, or by contacting other services where contacts may have attended.

Exceptions to achieving documentation of PN outcomes by four weeks include prioritizing urgent health needs (e.g. in an ill patient or a patient with multiple health problems), as well as disclosure issues (e.g. with regard to the management of people with HIV infection). These exceptions, as well as an agreed time frame for resolution, should be clearly documented.

(12) Legal issue regarding sharing of information between services

In England, The NHS Trusts and Primary Care Trusts (Sexually Transmitted Diseases) Directions 200030 allow information to be shared about people with sexually transmitted infections for the purpose of control of infection, and support one service informing another service whether a contact has attended that service. In particular, the 2000 Directions maintain the principles in the The National Health Service (Venereal Diseases) Regulations 196825 and the instructions in the accompanying Memorandum,26 which describe good practice in contact tracing. The 2000 Directions will require review to account for the current organizational reform of health-care services in England. In Wales the National Health Service Trusts (Venereal Diseases) Regulations 1974 and the 1968 Memorandum continue to apply. (Communication from Betsi Cadwaladr University Health Board with regard to advice provided to Betsi Cadwaladr University for the purpose of their own internal governance.) Similar good practice of sharing information between services is well-established in Scotland and Northern Ireland without there being any equivalent legislation.

(13) PN auditable outcome measures for the BASHH Clinical Effectiveness Group Guidelines and National Audit Group audit questionnaires

The following four process outcome measures are intended for use in the ‘Auditable Outcome Measures’ section of future relevant CEG Guidelines, as well as in National Audit Group audit questionnaires, that deal with infections requiring PN. These measures may be applied to all the infections in the table in Section 9, (but see the comments about HIV PN in the table in Section 9):

(1) The percentage of index cases documented as offered at least one discussion, which may be a telephone discussion, for the purpose of PN with a HCW with the appropriate documented competency. Performance standard 97%.

(2) The percentage of index cases having the outcome of (an) agreed contact action(s), or the decision not to contact, documented for all contacts. Performance standard 97%.

These 97% performance standards are to allow for one case in forty audited not having the recommended documentation owing to a random performance lapse not accounted for in a list of exceptions or exclusions (that would be determined before auditing), or a single data entry error. Forty is the minimum number of cases suggested for audits by the Royal College of Physicians Clinical Effectiveness and Evaluation Unit.33

(3) The number of all contacts of index cases whose attendance at a Level 1, 2 or 3 sexual health service was documented as reported by the index case, or by an HCW, within four weeks of the date of the first PN discussion*.

The current performance standards for index-reported gonorrhoeal PN are: at least 0.4 contacts per index case in large city clinics (London, Birmingham and Manchester), or at least 0.6 contacts in other clinics, and documented within four weeks of the date of the first PN discussion.8 Section 14 below deals with the updated chlamydial index-reported PN outcome standards. More work is needed to determine standards for this measure for other infections.

(4) The number of all contacts of index cases whose attendance at a Level 1, 2 or 3 sexual health service was documented as verified by a HCW, within four weeks of the date of the first PN discussion*. See Section 11 above for the interpretation of ‘verified.’ Section 14 below deals with the updated chlamydial
HCW-verified PN outcome standard. More work is needed to determine standards for this measure for other infections. The first PN discussion is the first discussion (including a telephone discussion) for the purpose of PN between the index case and a HCW with the appropriate documented competency.

(14) Updated chlamydial PN outcome standards and rationale for the updated standards

The updated chlamydial PN outcome standards are:

- **Index-reported:** At least 0.6 contacts per index case, with contact attendance at a Level 1, 2 or 3 sexual health service documented as reported by the index case, or by an HCW, within four weeks of the date of the first PN discussion. This applies to all clinics, both outside London and in London.

- **HCW-verified:** At least 0.4 contacts per index case, with contact attendance at a Level 1, 2 or 3 sexual health service, documented as verified by an HCW, within four weeks of the date of the first PN discussion. This applies to all clinics, both outside London and in London.

The appendix in Section 21 provides notes on measuring the updated chlamydial PN outcome measures.

The previous outcome standard to chlamydial PN outcome was at least 0.4 contacts screened per index case within a large city (London, Manchester, Birmingham) or at least 0.6 contacts screened per index case elsewhere, and within four weeks from diagnosis, and variations of this loosely defined standard have been used by the BASHH CEG Guideline on the management of genital chlamydial infection, the BASHH MedFASH Standards for the management of sexually transmitted infections, and by the UK National Chlamydial Screening Programme. The previous standard is based on a number of different audits and surveys, which used various methodologies, and all of which are more than ten years old, and where process outcomes for index case-reported and HCW-verified contact events could not be differentiated. Additionally, the 2011 BASHH Audit against the Key Performance Indicators in the BASHH MedFASH STI Management Standards (STIMS) Audit used a uniform methodology and provides a large amount of current data on PN performance that allows updating of the previous standard, including the proposal of new standards for HCW-verified contact attendance. Performance has changed since the data supporting the previous standard were published: in the STIMS Audit index case-reported contact attendance for Level 3 clinics in London is now higher than that for Level 3 clinics outside London (see below).

Performance data from the STIMS Audit, on which the updated PN standards are based, are summarized in the table below:

<table>
<thead>
<tr>
<th>Median number of contacts seen per index case in Level 3 clinics in the 2011 STIMS Audit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Verified by a HCW</strong></td>
</tr>
<tr>
<td>Outside London clinics that provided data for 40 cases (n = 62 clinics):</td>
</tr>
<tr>
<td>London clinics that provided data for 40 cases (n = 37 clinics):</td>
</tr>
</tbody>
</table>

The 0.6 standard for index case-reported contact attendance has remained the same for clinics other than large city clinics (London, Birmingham and Manchester). There are three main changes:

- **Clinics are grouped as outside London or London clinics, instead of other and London/large city.** The original grouping in the review that set the previous PN standard for chlamydial infection was ‘London/large city’ (qualified as London, Birmingham and Manchester) and ‘Other’, since referred to as ‘large conurbation’ and ‘elsewhere’ in the STIMS. The STIMS Audit reported on performance for clinics in London and clinics outside London. The reason for this was that there is lack of current PN performance data to support grouping particular large cities with London, and there are other large cities with similar or greater population densities compared to Birmingham and Manchester.

- **More recent chlamydial PN performance in three large genitourinary medicine clinics in the West Midlands is closer to the 0.6 standard.** Additionally, more recent national audits have presented London chlamydial PN performance data separately. In the STIMS Audit, the four participating clinics in Birmingham and Manchester had a median index case-reported contact attendance of 0.49 contacts per index case, lower than the median for the London clinics and closer to that of other clinics outside London.

- **The standard for index case-reported contact attendance for large city clinics, including London clinics, is now 0.6.** This is based on performance and acceptability factors. The previous standard for index case-reported contact attendance for London clinics was 0.4, but the median performance for London clinics in the STIMS Audit for this measure was 0.8. Rather than propose a new standard which is double that of the previous standard, 0.6 is recommended as a standard that would be more acceptable. A recent publication on PN performance from a London clinic supports the 0.6 standard (with 64% of patients with chlamydia having at least one partner treated within 4 weeks, mainly based on patient report and a well-designed electronic data recording system).

- **Measurement of verified contact attendance is now recommended, and the standard for verified contact attendance is the same for outside London and London clinics.** Verified contact attendance reflects best practice in PN because it allows ascertainment of whether contacts were actually appropriately seen, and provides a reliable measure of the Public Health impact of PN work. However, verifying contact attendance requires more support and resources, including dedicated time in job plans and administrative support for HCWs to do this work, as well as support from managers and commissioners.

The outside-London standard for verified contact attendance is at least 0.4 contacts. This is based on performance and acceptability factors. Even though median verification performance for clinics outside London is 0.6, a lower standard at 0.4 is recommended. This is because verification may be generally considered to be easier to achieve than patient-reported contact attendance, and the 0.4 standard may be more acceptable to clinics outside London.
The London standard for verified contact attendance is also at least 0.4 contacts. Slightly more than half of all London clinics submitting performance data on 40 cases had a median verification rate of 0.35. This value has been rounded up to 0.4.

(15) **Interface between PN and outbreak/incident control**

PN has a prime role in the control of outbreak of STIs, including blood borne infection, and these are occasions when HCWs providing PN should work closely with local HPUs. Guidance on dealing with infection outbreaks and collaborating with local HPUs for England is provided in the Health Protection Agency *Guidance for Managing STI outbreaks and incidents.*

The HPA defines an STI outbreak/incident as one of the following:

- An observed number of cases that is greater than expected over a defined time period in a given community. This could amount to a small number of cases;
- Linked cases that are of public health significance;
- A situation that requires the re-organization of services or development of additional resources to diagnose and manage cases.

The Guidance also emphasizes the need for local clinicians to review clinical data in order to detect and act on outbreaks. Where a potential outbreak or incident has been identified, the HPU can support the management of the outbreak/incident, including liaison with adjacent localities as appropriate. Typically there three phases of outbreak/incident control:

- **Phase 1 (Preliminary):** an incident team is convened to determine whether a problem exists and, if so, what action to take next;
- **Phase 2 (Control):** an outbreak control team (OCT) develops and implements strategies to limit onward transmission of infection, using a variety of investigation and control approaches;
- **Phase 3 (Evaluation):** a process evaluation, and assessment of success using primary outcome measures is undertaken, with audit as necessary.

An example of an incident jointly managed in this way is described in a recent publication.

(16) **Safeguarding children and vulnerable adults**

HCWs should distinguish between obtaining information on sexual partners for the purpose of PN and when such information may be used for the purpose of protecting children or vulnerable adults. If there are concerns about a sexual partner and the risk of sexual abuse or exploitation, or if such concerns arise as a result of asking questions for PN, (further) questions should not be asked for PN purposes without firstly stating that any information obtained may be passed on to safeguarding services. Information obtained as a result of asking questions for PN purposes that raises concerns about abuse or exploitation in children or adults should be managed according to the BASHH Guideline on the management of STIs and related conditions in children and young people, and local guidelines on safeguarding adults, respectively.

(17) **HIV-PN**

The development of outcome measures and standards for HIV-PN, to drive improved HIV-PN performance, is urgently needed in the face of a growing epidemic of HIV infection. This should be supported by the same principles described above. Appropriate resources should be provided to those involved in HIV-PN. This should extend to outreach work, including working effectively with workers involved with high-risk venues, the voluntary sector and web-based social network sites. Approaches may need to be tailored for specific at risk groups (e.g. men who have sex with men and Black and ethnic minority groups). The more intensive support that is often needed in helping people with HIV infection to involve contacts should have the necessary management and funding.

Clinics should review their systems intended to support HIV-PN, including record-keeping. Although there are currently no standards against which to measure HIV-PN outcomes, clinics should also regularly measure HIV-PN outcomes – these data will help inform the future development of performance standards.

(18) **Future developments in PN outcome measurement**

Verification of PN process outcomes, with evidence of contact management, rather than index patient-reported process outcomes, may be of greater value in future national performance reporting systems. This may be particularly important for future evidence-based commissioning of services. The development of secure, patient-centred, web-based solutions, such as electronic PN, that can verify contact management will be important in providing tools to support such reporting.

Currently, there is reliance on performance data from audits to recommend outcome standards. Also, the available audit data mainly provide patient-centred process outcomes (e.g. contacts seen per index case) that conceal the variability in transmission likelihoods associated with different types of contact (e.g. live-in, regular and casual). The measurement of PN process outcomes related to contact-centred outcomes, and epidemiological measures of transmission interruption, may be a better estimation of the impact, and optimal use, of resources for PN, as suggested in a study by Mercer *et al.* Further work is needed on the epidemiological approach to measuring PN impact on local populations and setting PN performance standards.

(19) **Contributors**

The following contributed to this statement: Steven Akehurst on behalf of the National AIDS Trust, Janice Allan, Steve Baguley, Helen Bailey, Gill Bell, Sumit Bhaduri, Gary Brook, Chris Carne, Jackie Cassell, Katherine Coyne, Suzanne Davison, Wallace Dinsmore, Rachael Elliks on behalf of the BASHH Cheshire and Mersey Branch, Carol Emerson on behalf of the BASHH Northern Ireland Branch, Claudia Estcourt, Steven Estreich, Ceri Evans, Mark FitzGerald, Patrick French, Madeleine Greaves, Patrick Horner, Beverly Ibbetson, Margaret Kingston, Nicola Low, Philippe Mayaud, Martin Murchie on behalf of the Society for Sexual Health Advisers, Colm O’Mahoney, Rachel Parker, Ray Poll, Jonathan Roberts on behalf of the Claude Nicol...
Centre in Brighton, Karen Rogstad, Jonathan Ross, Hannah Sale, Gordon Scott, Jackie Sherrard, Peter Watson, David Wilson, and Andrew Winter.

(20) Document review plan
This Statement will be reviewed by the BASHH CEG in 2015, or earlier if a reason for change is presented to the BASHH CEG.

(21) Appendix. Notes on measuring the updated chlamydial PN outcome measures
The following describe how chlamydial PN outcome measures should be calculated.

**Reported contact attendance**

**Numerator:** The total number of contacts, of index cases with Sexual Health and HIV Activity Property Type (SHHAPT) code C4, whose attendance at a Level 1, 2 or 3 sexual health service was documented as reported by the index case, or by an HCW, within four weeks of the date of the first PN discussion, and during a specified interval.

**Denominator:** The total number of index cases with SHHAPT code C4 managed by the service during the same interval.

**Verified contact attendance**

**Numerator:** The total number of contacts, of index cases with SHHAPT code C4, whose attendance at a Level 1, 2 or 3 sexual health service was documented as verified by an HCW, within four weeks of the date of the first PN discussion, and during a specified interval.

**Denominator:** The total number of index cases with SHHAPT code C4 managed by the service during the same interval.

The C4 SHHAPT code should be used only once per patient episode, so it is important to appropriately close episodes in registration systems to allow for cases re-presenting with new chlamydial infection to be included in the numerator. That is, cases thought to be newly infected after a previous episode of chlamydia should be regarded as a new GUM episode and coded accordingly. Please refer to the Genitourinary Medicine Clinic Activity Dataset Guidance about correct use of the C4 code. If C4 is used more than once in an audit interval, only contacts thought to be involved in the new episode should be counted.

When counting the number of index-reported contact attendances, include:

- Contacts with attendance verified by an HCW, even if there is no record of attendance reported by an index case. Many contacts with verified attendance will also have reported attendance. However, it may be possible to record that a contact was verified as having attended the same clinic (or another clinic), without this being reported by an index case, provided that sufficient baseline contact information was obtained. Counting verified attendance in with reported attendance is intended to facilitate the counting of contacts for the purpose of audits and improve consistency between clinics. This means that the number of index-reported contacts should be greater than the number of verified contacts;

- Contacts reported as attending by an HCW. An HCW may have received information, other than from the index case, that a contact has attended a service managing STIs, without verifying this by contacting that service.

It may not be possible to verify contact attendance, e.g. when there is no information about where a contact may have attended. However, as a minimum, a clinic’s own records should be checked for contact attendance. Also, please see the comments above in the future developments section (Section 18).

**REFERENCES**

16. British HIV Association, British Association for Sexual Health and HIV and the Faculty of Sexual and Reproductive Healthcare. *UK Guidelines for the*
Management of Sexual and Reproductive Health (SRH) of People Living with HIV Infection. See http://www.bashh.org/documents/1955 (last checked 27 February 2012)


22 Health Protection Agency. List of Notifiable Diseases. See http://www.hpa.org.uk/Topics/InfectionsDiseases/InfectionsAZ/NotifiableDiseases/ListOfNotifiableDiseases/ (last checked 1 February 2012)

23 Health Protection Agency. Health Protection Units. See http://www.hpa.org.uk/web/HPAwebHPAwebStandard/HPAweb_C/1219908762203 (last checked 5 February 2012)


28 Kanno M, Sobel JD. Late recurrence of resistant Mycoplasma genitalium in asymptomatic patients: implications for screening. Sex Transm Infect 2009;85:436–7


35 National Chlamydia Screening Programme. NCSP Core Requirements Fifth Edition (NCSP Standard 4). See http://www.chlamydiadischarging.nhs.uk/ps/publications/core.html (last checked 19 September 2012)


43 Rogstad K, Thomas A, Williams O, et al. United Kingdom National Guideline on the Management of Sexually Transmitted Infections and Related Conditions in Children and Young People on behalf of the British Association for Sexual Health and HIV. See http://www.bashh.org/documents/2674 (last checked 1 February 2012)


46 Health Protection Agency and British Association for Sexual Health and HIV. Genitourinary Medicine Clinic Activity Dataset Guidance to Clinic Staff. See http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1234859711509 (last checked 22 September 2012)